Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of “Hold” by Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has received an average rating of “Hold” from the nine analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $20.50.

KROS has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a report on Wednesday, August 12th. Leerink Partners decreased their price objective on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 4th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday, August 4th. Finally, Wall Street Zen lowered Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, September 5th.

Keros Therapeutics Stock Performance

Shares of KROS opened at $11.17 on Friday. The stock has a market capitalization of $221.50 million, a PE ratio of -3.02 and a beta of 1.01. The company’s fifty day moving average is $10.83 and its 200 day moving average is $11.22. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 21.40%. As a group, research analysts forecast that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its board has approved a stock repurchase program on Wednesday, September 9th that permits the company to buyback $5.00 million in shares. This buyback authorization permits the company to repurchase up to 2.3% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, insider Lorena Raquel Lerner sold 3,568 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the sale, the insider owned 27,559 shares of the company’s stock, valued at approximately $283,582.11. This represents a 11.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 5,343 shares of company stock worth $54,985 in the last quarter. Insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in KROS. California State Teachers Retirement System grew its holdings in Keros Therapeutics by 72.6% during the 2nd quarter. California State Teachers Retirement System now owns 2,729 shares of the company’s stock valued at $29,000 after purchasing an additional 1,148 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in Keros Therapeutics by 254.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares during the period. Tower Research Capital LLC TRC lifted its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock worth $42,000 after purchasing an additional 1,888 shares during the last quarter. Legal & General Group Plc bought a new stake in Keros Therapeutics in the second quarter worth about $90,000. Finally, PDT Partners LLC purchased a new position in shares of Keros Therapeutics during the second quarter valued at approximately $122,000. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.